Comparative effects of injecting 5,6-dihydroxytryptamine in the dorsal or medial raphe nuclei on rat puberty.
The role played by the serotoninergic system in the control of puberty onset and first ovulation in rats is studied in this paper by analyzing the effects of injecting the neurotoxin 5,6-dihydroxytryptamine (5,6-DHT) into the dorsal (DRN) or medial (MRN) raphe nucleus of 30-day-old female rats. Complete lesion to the DRN resulted in the blockade of ovulation and a decrease in both the number of ovarian follicles and the serum concentration of follicle stimulating hormone (FSH). This treatment was also found to be associated with an increase in serotoninergic activity in the anterior and medial hypothalami. A lesion to the central portion of the DRN resulted in a significant decrease in the concentration of progesterone in serum and in the number of ova shed by ovulating animals. The lesion to the lateral portion of the DRN did not have an apparent effect on ovulation rate, the number of ova shed, nor in hormone serum concentration. The injection of propranolol to rats with a lesion to the DRN restored ovulation in 73% of treated animals and returned serotoninergic activity in the anterior hypothalamus to levels similar to those of sham-operated animals. In turn, in the medial hypothalamus, the increase in serotoninergic activity was not modified. The results presented herein suggest that serotoninergic inputs to the anterior hypothalamus have a direct influence on gonadotropin secretion and first ovulation, while the noradrenergic innervation exerts an indirect influence.
Monroy
Juana
J
Laboratory of Puberty, Biology of Reproduction Research Unit, Facultad de Estudios Superiores Zaragoza, UNAM, AP 9-020, CP 15000, México, DF, Mexico.
Ayala
María Elena
ME
Chavira
Roberto
R
Damián-Matsumura
Pablo
P
Domínguez
Roberto
R
D015115:5,6-Dihydroxytryptamine / Q000008:administration & dosage* / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001931:Brain Mapping; D004958:Estradiol / Q000097:blood; D004971:Estrus / Q000187:drug effects / Q000378:metabolism; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism; D007986:Luteinizing Hormone / Q000378:metabolism; D020645:Mediodorsal Thalamic Nucleus / Q000187:drug effects* / Q000502:physiology; D006080:Ovarian Follicle / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D010060:Ovulation / Q000187:drug effects / Q000378:metabolism; D011374:Progesterone / Q000097:blood; D011433:Propranolol / Q000494:pharmacology; D011903:Raphe Nuclei / Q000033:anatomy & histology / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D011919:Rats, Inbred Strains; D018490:Serotonin Agents / Q000008:administration & dosage* / Q000494:pharmacology; D014621:Vagina / Q000187:drug effects / Q000378:metabolism
D000319:Adrenergic beta-Antagonists; D018490:Serotonin Agents; D011374:Progesterone; D004958:Estradiol; D006897:Hydroxyindoleacetic Acid; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D011433:Propranolol; D015115:5,6-Dihydroxytryptamine